Abiopharma

News list

Amphastar (AMPH)

Event
Aug. 08, 2022, 20:23 UTC

(79% Neutral) Amphastar Pharmaceuticals, Inc. (AMPH) Reports Q3 2022 Financial Results

Full text

News bot Oct. 2, 2025, 11:32 p.m.

📋 Amphastar Pharmaceuticals, Inc. (AMPH) - Financial Results

Filing Date: 2022-08-08

Accepted: 2022-08-08 16:23:39

Event Type: Financial Results

Event Details:

Amphastar (AMPH) Reports Q3 2022 Financial Results Amphastar (AMPH) announced its financial results for the period ending Q3 2022. Key Financial Highlights:

Revenue: 60111
Net Income: 20730
EPS: 0.39
Cash and equivalents: 166157
- targeting products with a market size of over $3 billion, three biosimilar products in development targeting products with a market size of over $12 billion, and eight generic products in development targeting products with a market size of over $9 billion. This market information is based on IQVIA data for the 12 months ended June 30, 2022

📊 Key Financial Metrics (Year-over-Year Comparison):

Metric	2022	2021	Change ($)	Change (%)
Current Assets Prepaid Expenses Other Current Assets	5.90K	5.90K	$0.00	+0.00%
Property Equipment Net	237.56K	237.56K	$0.00	+0.00%
Operating Lease Right Of Use Assets	26.96K	26.96K	$0.00	+0.00%
Other Assets	18.68K	18.68K	$0.00	+0.00%
Other Long Term Liabilities	15.33K	15.33K	$0.00	+0.00%

💼 Business Developments:

Partnership: Not available
Acquisition
Licensing: Not available
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: Amphastar
CIK: 0001297184
Ticker Symbol: AMPH
Period End Date: 2022-08-08
Document Type: 8-K